Clinical genomics, read and reviewed for you
Every week, the most relevant publications in constitutional genetics, hereditary cancer, pharmacogenomics and bioinformatics — curated, scored against a public grid and reviewed by a medical biologist. Free, ad-free.
Every week, ~600 publications are screened down to a curated, scored selection — over ~6,500 publications examined since launch.
This week on Geno'X
Four domains, one report per week each.
An umbrella review synthesizes 17 systematic reviews covering 211 pharmacoeconomic evaluations on the cost-effectiveness of preemptive pharmacogenetic testing. The main finding is striking: 71.1% of the 211 studies conclude that preemptive genotyping is cost-effective. The temporal trend is favorable, with an increasing proportion of positive studies from the emergence of the literature through October 2025. Data cover multiple genes and clinical contexts, with recognizable geographic limitations.
The watch in numbers
Selection funnel, score distribution, most-covered genes — the full curation mechanics, in the open.
Explore the watch in numbersHow it works
1. Exhaustive collection
Every week, PubMed, around a hundred specialty journals and bioRxiv/medRxiv preprints are screened across all 4 domains.
2. Transparent scoring
Each article is scored out of 10 against a public 5-criteria grid — clinical impact first. The score breakdown is shown on every article page.
3. Signed expert analysis
Every selected article is read and reviewed by a medical biologist: bilingual FR/EN summary and critical perspective — no black-box generated digest.
The full scoring grid is public: see the methodology.
Who is behind Geno'X?
Geno'X Veille is published by Dr Thibaut Benquey, a medical biologist specializing in constitutional genomics (WGS/WES) — from rare disease diagnosis to the clinical applications of next-generation sequencing. Every article is personally curated, scored and reviewed: no mass-generated content, no black box.
Follow on LinkedInWhy it's free
Geno'X Veille is a personal project — no ads, no sponsors, no sponsored content. No data is ever sold. The goal isn't commercial: it's to make clinical-genomics literature monitoring accessible to the whole community — biologists, geneticists, residents, genetic counsellors.
If you find the project useful, you can support hosting and curation time via Ko-fi — entirely optional.
Support on Ko-fiEvery Wednesday · Annotated selection · Free · Unsubscribe anytime